Cerebral blood flow (CBF) was studied at normocapnia and-after a challenge with 5% CO, in 59 diabetic patients and 28 controls. There was a significant age-related decline in CBF in both groups, which suggests that diabetes does not affect the rate of decrease of CBF with age.
Introduction
In view of the high incidence of cerebrovascular disease in diabetics1-3 we decided to study cerebral blood flow (CBF) in patients with diabetes mellitus and control patients. We investigated the flow at normocapnia and the vasodilatation reserve in response to hypercapnia. We also assessed the effect of age on flow in both groups.
Results
CBF at normocapnia was similar in the diabetic patients and controls. There was a significant reduction in CBF with age in the diabetics (r = -083, P < 0-001- fig 1) , which was similar to that in the normal population (r = -077, P < 0 001- fig 2) . The regression of CBF with age was given by CBF = 608 -(033 x age) in controls and CBF = 71 03 -(048 x age) in diabetics. Some of the diabetics, however, appeared to maintain CBF at levels higher than would be expected for their age. Haemoglobin concentration did not increase with age.
In all but four of the controls there was a significant increase in 
Discussion
Our observations indicate a significant age-related decline in CBF in both controls and diabetics. The values of CBF and the rates of decline were similar to those found by Crawley and Veall9 in normal people. The slopes of regression lines for diabetics and controls were similar in our study, suggesting that diabetes does not.significantly alter the rate of decline of normocapnic CBF with age. Increased viscosity of the blood has been found in diabetic patients, suggesting that blood flow through organs of diabetics may be impaired.'0 Increased viscosity due to a high packed cell volume may also be associated with reduced CBF." Since CBF was normal other factors may compensate for increased viscosity in diabetes. The reactivity of cerebral vessels to CO2 is noticeably altered in diabetics, most of whom show either no increase or a decrease in flow after CO2 administration. The effect of blood viscosity on cerebral vascular reactivity needs to be investigated.
Whereas rapidly developing atherosclerosis with loss of elasticity and ability to dilate may account for the loss of vascular reactivity in older diabetics, this is unlikely to be the cause in younger patients. Furthermore, the paradoxical fall in CBF after inhalation of CO2 suggests that the latter has a biphasic effect on cerebral blood vessels. Thus some form of neurohumoral dysregulation or alteration in receptors on vascular smooth muscle is probably the cause of altered reactivity of cerebral vessels in diabetes. Newly discovered diabetics without autonomic neuropathy, retinopathy, or other complications also had the abnormality. Since this loss of reactivity was not observed in even the very elderly controls, it appears to be linked specifically to diabetes. A loss of CO2 reactivity has been described in patients with encephalopathy, as in hepatic coma, but the control of these diabetics was reasonable, and none exhibited significant neurological disturbance.
Because the rate of decline of normocapnic CBF with age in diabetics is similar to that in the normal population and the response to CO2 is altered o* diminished, we suggest that future studies assessing risk factors in cerebrovascular disease should include CO, reactivity as an additional indicator of diminished cerebrovascular reserve. These findings are clinically relevant: although the rate of overt cerebrovascular disease increases with age in both normal patients and diabetics, the diabetics are at particular risk because of their inability to compensate with increased CBF when metabolic requirements of the brain demand. this. Similarly the response to hypotension might be affected if vasodilatation were compromised.
The impaired ability of cerebral vessels to dilate is an early and undescribed complication of diabetes mellitus, which may be important in the pathogenesis of cerebrovascular disease in diabetics.
